¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reduced substrate concentration"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® concentration ÇÑ±Û ³óµµ, ÁýÁß
¼³¸í   
  1. ³óµµ. ¿ë¾×À̳ª ¿ë¸ÅÀÇ Áú·® ¶Ç´Â Ã¼Àû¿¡ ´ëÇÑ ¿ëÁúÀÇ Áú·® ¶Ç´Â Ã¼Àû. 2. ÁýÁß. °øÅëÀÇ Áß½ÉÀ¸·Î ¸ô¸®´Â ÇÑ Á¡¿¡ ÁýÇÕÇϴ °Í.
¿µ¹® pH, hydrogen ion concentration ÇÑ±Û ¼ö¼ÒÀ̿³óµµÁö¼ö
¼³¸í   
  Ç÷¾×À̳ª ¼Òº¯¿¡¼­ ½Ç½ÃÇϴ °Ë»çÇ׸ñ. pH°Ë»ç´Â ÀÎüÀǠü¾×ÀÇ »ê¼º, ¾ËÄ®¸®¼ºÀ» ¾Ë¾Æº¸´Â Áß¿äÇÑ °Ë»çÀÌ´Ù. ÀÎü´Â ¾à¾ËÄ®¸®¼º¿¡ ¼ÓÇϳª, À̺¸´Ù pHÀÇ Áõ°¡³ª °¨¼Ò°¡ ³ªÅ¸³¯ °æ¿ì, »ý¸í¿¡ À§ÇèÀÌ ¹ß»ýÇÑ´Ù. ÀÎü³»¿¡´Â ÀÌ·± »êµµÀÇ Áõ°¨À» ¸·±âÀ§ÇØ, À̸¥¹Ù ¿ÏÃæÁ¦µéÀÌ ¸¹ÀÌ Á¸ÀçÇϸç, Æ¯È÷ ÇãÆÄ¿Í ÄáÆÏÀÌ ¿ÏÃæÀÛ¿ëÀ» ¼öÇàÇϴ ÁÖ¿ä±â°üÀÌ´Ù.
  
  ÄáÆÏÀº »êµµ°¡ ³ôÀ» °æ¿ì, ¼Òº¯¿¡¼­ »êµµ¸¦ Áõ°¡½ÃÄÑ ¹èÃâÇÔÀ¸·Î½á Ç÷¾×³»ÀÇ ¾ËÄ®¸®¼º ³óµµ°¡ Áõ°¡Çϵµ·Ï ÇÑ´Ù. ¶ÇÇÑ ÇãÆÄ¿¡¼­µµ, Ç÷¾×³»¿¡ »êµµ°¡ Áõ°¡½Ã È£ÈíÀ» Áõ°¡ÇÔÀ¸·Î½á ¹ÛÀ¸·Î »êÀÇ ¹èÃâÀ» Áõ°¡½ÃŲ´Ù. ÀÌ·± ÇãÆÄ¿Í ÄáÆÏÀÇ ±ÕÇüÀº ¾ÆÁÖ ÀûÀýÈ÷ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ¾î´À ÇÑ ±â°üÀÇ ÀÌ»óÀÌ ¹ß»ýÇϸé, ÀÌ·± ±ÕÇüÀº ±ú¾îÁö±â ½±´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • reduced bandwidth technique
    Á֯ļöÆø°¨¼Ò±â¹ý
  • reduced flavoprotein
    ȯ¿øÇüÇöóºó´Ü¹éÁú
  • reduced hemoglobin
    ȯ¿øÇ÷»ö¼Ò, ȯ¿øÇì¸ð±Û·Îºó
  • reduced pelvis
    Ãà¼Ò°ñ¹Ý
  • reduced penetrance
    °¨Åð¹ßÇö
  • renin substrate
    ·¹´Ñ±âÁú
  • respiratory substrate
    È£Èí±âÁú
  • substrate
    ±âÁú
  • substrate mycelium
    ±âÁú±Õ»çü
  • blood concentration
    Ç÷Áß³óµµ
  • concentration
    1. ³óÃà 2. ³óµµ 3. ÁýÁß
  • concentration effect
    ³óµµÈ¿°ú
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reduced hemoglobin
    ȯ¿øÇ÷»ö¼Ò
  • concentration
    ³óµµ, ÁýÁß
  • blood concentration
    Ç÷Áß³óµµ
  • stress concentration
    ÀÀ·ÂÁýÁß
  • substrate
    ±âÁú
  • renin substrate
    ·¹´Ñ±âÁú
  • respiratory substrate
    È£Èí±âÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • substrate-labeled fluorescence immunoassay
    ±âÁúÇ¥ÁöÇü±¤¸é¿ªºÐ¼®(¹ý)
  • substrate mycelium
    ±âÁú±Õ»çü
  • renin substrate
    ·¹´Ñ±âÁú
  • respiratory substrate
    È£Èí±âÁú
  • substrate
    ±âÁú
  • reduced flavoprotein
    ȯ¿øÇüÇöóºó´Ü¹éÁú
  • reduced heat
    ȯ»ê¿­·®
  • reduced hemoglobin
    ȯ¿øÇ÷»ö¼Ò
  • reduced pelvis
    ÇùÂø°ñ¹Ý, Ãà¼Ò°ñ¹Ý
  • reduced penetrance
    °¨Åð¹ßÇö
  • reduced bandwidth technique
    Á֯ļöÆø°¨¼Ò±â¹ý
  • blood concentration
    Ç÷Áß³óµµ
  • concentration
    ³óµµ, ÁýÁß
  • concentration effect
    ³óµµÈ¿°ú
  • concentration calibrated vaporizer
    ³óµµÁ¶Àý±âÈ­±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • SLFIA => substrate-labeled fluorescence imunoassay
    ±âÁúÇ¥ÁöÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • hippurate substrate
    ¸¶´¢»ê±âÁú
  • renin substrate
    ·¹´Ñ±âÁú.
  • Gullstrands reduced eye
    ±¼½ºÆ®¶õµå»ý·«¾È
  • reduced bandwidth technique
    Á֯ļöÆø °¨¼Ò ±â¹ý
  • reduced body temperature
    Àúü¿Â(¹ý) (î¸ô÷è®Ûö).
  • reduced eye
    »ý·«¾È(ßèå²äÑ).
  • reduced flavoprotein
    ȯ¿øÇüÇö󺸴ܹéÁú.
  • reduced heat
    ȯ»ê¿­·®(üµß©æðåÖ).
  • reduced hemoglobin
    ȯ¿øÇ÷»ö¼Ò(ü½êª úìßäáÈ).
  • reduced hemoglobin
    ȯ¿øÇ÷»ö¼Ò(ü½êªúìßäáÈ)
  • reduced illumination
    °¨¾àÁ¶¸í(˧ËâÌ¡ËÎ).
  • reduced iron ³ª ferrum reductum
    ȯ¿øÃ¶(ü½êªôÑ).
  • reduced mass
    ȯ»êÁú·®(üµß©òõåÖ).
  • reduced pelvis
    ÇùÂø°ñ¹Ý(úõó¸ÍéÚï)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hippurate substrate
    ¸¶´¢»ê±âÁú
  • leading substrate
    ¼±µµ±âÁú.
  • mycelium, substrate
    ±âÁú±Õ»çü
  • renin substrate
    ·¹´Ñ±âÁú.
  • respiratory substrate
    È£Èí±âÁú(û¼ýåѨòõ), È£Èí¹°Áú(û¼ýåÚªòõ).
  • substrate
    ±âÁú
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­.
  • substrate-labeled fluorescence immunoassay(sLFIA)
    ±âÁúÇ¥ÁöÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • edema,reduced oncotic pressure
    »ïÅõ¾Ð °¨¼Ò(ß¶÷âäâ Êõá´)
  • reduced bandwidth technique
    Á֯ļöÆø °¨¼Ò ±â¹ý
  • reduced body temperature
    Àúü¿Â(¹ý) (î¸ô÷è®Ûö).
  • reduced eye
    »ý·«¾È(ßèå²äÑ).
  • reduced flavoprotein
    ȯ¿øÇüÇö󺸴ܹéÁú.
  • reduced heat
    ȯ»ê¿­·®(üµß©æðåÖ).
  • reduced hemoglobin
    ȯ¿øÇ÷»ö¼Ò(ü½êªúìßäáÈ)
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • concentration technique
    Áý¶õ¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reduced substrate concentration
    ȯ»ê ±âÁú ³óµµ(üµß©Ñ¨òõÒØÓø)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • normalized substrate concentration
    ³ë¸£¸» ±âÁú³óµµ(ѨòõÒØÓø)
  • relative substrate concentration
    »ó´ë ±âÁú³óµµ(ßÓÓßÐñòõÒØÓø)
  • saturating substrate concentration
    Æ÷È­ ±âÁú³óµµ(øéûùÐñòõÒØÓø)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
  • reduced mean residue rotation
    ȯ»ê Æò±Õ Àܱâ ȸÀü(üµß©øÁгíÑÐñüÞï®)
  • reduced osmotic pressure
    ȯ»ê »ïÅõ¾Ð(üµß©ß¶÷âäâ)
  • reduced scattered light intensity
    ȯ»ê »ê¶õ±¤ °­µµ(üµß©ß¤Õ¯ÎÃË­Óø)
  • reduced viscosity
    ȯ»ê Á¡µµ(üµß©ïÄÓø)
  • active concentration
    Ȱ¼º³óµµ(üÀàõÒØÓø)
  • concentration
    ³óµµ(ÒØÓø)
  • concentration equilibrium constant
    "³óµµÆòÇü»ó¼ö(ÒØÓøøÁû¬ßÈâ¦), (ÔÒ) apparent equilibrium constant"
  • concentration gradient
    ³óµµ ±¸¹è(ÒØÓøÎþÛÕ)
  • concentration of enzymatic activity
    È¿¼ÒȰ¼º ³óµµ(ý£áÈüÀàõÒØÓø)
  • concentration work
    ³óµµÀÛµ¿(ÒØÓøíÂÔÑ)
  • constituent concentration
    ±¸¼º¹° ³óµµ(ϰà÷ÚªÒØÓø)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reduced
    °¨ÅðÇÑ
  • reduced bandwidth technique
    ´ëÆø°¨¼Ò±â¹ý
  • blood concentration
    Ç÷Áõ³óµµ
  • concentration
    ³óµµ, ³óÃà, ÁýÁß
  • permissible concentration
    Çã¿ë³óµµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MAC MacConkey [broth]; major ambulatory category; malignancy-associated changes; maximum allowable conce...
MPC marine protein concentrate; maximum permissible concentration; mean plasma concentration; meperidine...
EC effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme...
MCC mean corpuscular hemoglobin concentration; medial cell column; Medical Council of Canada; metacerebr...
MEC median effective concentration; middle ear canal; middle ear cell; minimum effective concentration
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
rcm Reduced and carboxymethylated
RFC Reduced folate carrier
RHAL Reduced haloperidol
RRM Reduced renal mass
SCR SEX COMBS REDUCED
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • reduced
    °¨ÅðÇÑ
    1. °ñÀýÀÇ Á¤º¹°ú °°ÀÌ ÀûÀýÇÑ À§Ä¡, ¹èÄ¡¿¡ µÇµ¹¸°. 2. ±Ý¼ÓÀÇ ÇüÀ¸·Î µÇµ¹¸°.
  • reduced dental epethelium
    ÅðÃà Ä¡»óÇÇ
  • reduced interoccusal distance
    ÀúÀ§ ±³ÇÕ
  • leading substrate
    ¼±µµ ±âÁú
  • neuroanatomic substrate
    ½Å°æ ÇØºÎÇÐÀû ±âÁú, ½Å°æ ÇØºÎÇÐÀû ¹°Áú
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­
  • zymolite µ¿ÀǾî=substrate.

    zymologist

    È¿¼ÒÇÐÀÚ
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • blood concentration
    Ç÷Áß ³óµµ
  • concentration
    ³óÃà
    1. Áõ¹ß¿¡ ÀÇÇÑ ³óµµÀÇ Áõ°¡. 2. ¿ë¾×À̳ª ¿ë¸ÅÀÇ Áú·® ¶Ç´Â üÀû¿¡ ´ëÇÑ ¿ëÁúÀÇ Áú·® ¶Ç´Â üÀû.
  • Concentration difference
    ³óµµ ±¸¹è, ³óµµ °æ»ç
  • concentration gradient
    ³óµµ °æ»ç
  • concentration-response curve
    ³óµµ ¹ÝÀÀ °î¼±
  • equivalent concentration
    ´ç·® ³óµµ
  • Fishberg concentration test
    Çǽ¬¹ö±× ³óÃà ½ÃÇè
    200§¢ ÀÌÇÏÀÇ ¾×ü°¡ µé¾î°£ Àú³á ½Ä»ç¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, ÀÌÈÄ¿¡´Â ¾Æ¹« °Íµµ ÁÖÁö ¾Ê´Â´Ù. ¾ß°£¿¡ ¹è¼³µÈ ¿ä´Â ¹ö¸®°í À̸¥ ¾ÆÄ§ÀÇ ¿ä¸¦ ¸ð¾Æ³õ°í, ÇǰËÀÚ´Â ÀáÀ» Àڸ鼭 1½Ã°£ ÈÄ¿Í 2½Ã°£ ÈÄÀÇ ¿ä¸¦ äÃëÇÑ´Ù. ÀÌ 3°¡ÁöÀÇ ¿ä Ç¥º» Áß ¾î´À Çϳª¶óµµ ºñÁßÀÌ 1.024 ¹Ì¸¸ÀÌ¸é ½Å ±â´É ºÎÀüÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
reduced enamel epithelium The several layers of the enamel organ remaining on the enamel surface after formation of enamel is completed.
Synonym: reduced enamel epithelium.
(05 Mar 2000)
reduced eye A simplified design of the ocular optical system, represented as having a single refracting surface and a uniform index of refraction; a model based on this concept is used in retinoscopy and ophthalmoscopy.
(05 Mar 2000)
reduced glutathione Glutathione acting as a hydrogen donor.
(05 Mar 2000)
reduced haematin 1. <biochemistry> Compounds of iron complexed in a porphyrin (tetrapyrrole) ring that differ in side chain composition. Haems are the prosthetic groups of cytochromes and are found in most oxygen carrier proteins.
2. <prefix> haem-, eaning relating to blood.
Origin: G. Haima
(21 Jun 2000)
reduced haemoglobin The form of Hb in red blood cells after the oxygen of oxyhemoglobin is released in the tissues.
(05 Mar 2000)
reduced interarch distance An occluding vertical dimension which results in an excessive interocclusal distance when the mandible is in rest position, and in a reduced interridge distance when the teeth are in contact.
(05 Mar 2000)
Listing's reduced eye A representation that simplifies calculations of retinal imagery: radius of anterior refracting surface, 5.1 mm; total length, 20 mm; distance of nodal point to retina, 15 mm.
(05 Mar 2000)
substrate <chemistry> A substance upon which an enzyme acts.
Origin: L. Stratum = layer
(18 Nov 1997)
substrate cycle <biochemistry> Any seqence of enzyme catalysed reactions in which the forward and reverse processes (catalysed by different enzymes) are consititutively active.
Frequently used to describe the cycle of phosphorylation and dephosphorylation of phosphatidyl inositol derivatives in cell membranes.
(05 Jan 1998)
substrate cycling A set of opposing, nonequilibrium reactions catalyzed by different enzymes which act simultaneously, with at least one of the reactions driven by ATP hydrolysis. The results of the cycle are that ATP energy is depleted, heat is produced and no net substrate-to-product conversion is achieved. Examples of substrate cycling are cycling of gluconeogenesis and glycolysis pathways and cycling of the triglycerides and fatty acid pathways. Rates of substrate cycling may be increased many-fold in association with hypermetabolic states resulting from severe burns, cold exposure, hyperthyroidism, or acute exercise.
(12 Dec 1998)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
substrate-level phosphorylation Synthesis of high-energy phosphate bonds through reaction of inorganic phosphate with an activated (usually) organic substrate.
(09 Oct 1997)
substrate specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
(12 Dec 1998)
suicide substrate A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
insulin receptor substrate-1 protein <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous
Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1
(05 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reduced
    ÁÙÀÎ;Ãà¼ÒÇÑ;°¨¼ÒÇÑ;ÇÒÀÎÇÑ;¿µ¶ôÇÑ;¸ô¶ôÇÑ;¼è¾àÇÑ;ȯ¿øÇÑ;±â¾àÀÇ
  • substrate
    ±âÁú(È¿¼ÒÀÇ ÀÛ¿ëÀ¸·Î È­ÇйÝÀÀÀ» ÀÏÀ¸Å°´Â ¹°Áú);(¼¼±ÕÀÇ)¹è¾ç±â
  • concentration
    ÁýÁß; Àü³ä
  • concentration
    ÁýÁß;Áý°á;Àü½ÉÀü·Â;ÁýÁß·Â;Àü·Å;³óÃà;(¾×üÀÇ)³óµµ;¼±±¤;³óÈ­;ÁýÁß¿¬±¸;¼ýÀÚ¸ÂÃ߱⠳îÀÌ
  • concentration camp
    Á¤Ä¡¹ü(Æ÷·Î)¼ö¿ë¼Ò
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á